SCHEMBL31663784

SCHEMBL31663784

CCCC(F)C(=O)Nc1ccc(OC[C@H]2CCCCN2C(=O)OC(C)(C)C)c(-c2c(C)ncnc2C)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
F2RL3 Q96RI0 4/20 0.36
EPHA2 P29317 1/20 0.35
KDR P35968 1/20 0.35
EPHB4 P54760 1/20 0.35
JAK2 O60674 2/20 0.35
FPR3 P25089 1/20 0.35
FPR2 P25090 1/20 0.35
JAK3 P52333 1/20 0.35
GPR119 Q8TDV5 2/20 0.34
PRMT5 O14744 1/20 0.34
CHEK2 O96017 1/20 0.34
MCHR1 Q99705 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31663763 0.86 NPC1 (0.44) ALOX5APFEN1MEN1KMT2AF2RL3
SCHEMBL31663788 0.86 NPC1 (0.44) ALOX5APFEN1MEN1KMT2AF2RL3
SCHEMBL31663765 0.86 NPC1 (0.44) ALOX5APFEN1MEN1KMT2AF2RL3
SCHEMBL31663796 0.84 JAK2 (0.41) ALOX5APFEN1MEN1KMT2AF2RL3
SCHEMBL31663811 0.84 FPR3 (0.39) ALOX5APFEN1MEN1KMT2AF2RL3
SCHEMBL31663807 0.84 NPC1 (0.44) ALOX5APFEN1MEN1KMT2AF2RL3
SCHEMBL31663806 0.81 HTR2A (0.40) JAK2JAK3MCHR1
SCHEMBL31663776 0.81 PTPN2 (0.44) MEN1KMT2AJAK2FPR3FPR2
SCHEMBL31663752 0.80 ALOX5AP (0.44) ALOX5APFEN1F2RL3GPR119CHEK2
SCHEMBL31663797 0.78 ALOX5AP (0.47) ALOX5APFEN1F2RL3JAK2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-4236937-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2025-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto HTR2A, HTR5A, HTR1A ALOX5AP 100/4885FEN1 2279/4885MEN1 4514/4885
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto HTR2C, HTR1A, HTR2A ALOX5AP 606/4885FEN1 3355/4885MEN1 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.